Company will initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, first MICA/B antibody clinical study in hematologic malignancies Follows ongoing clinical study of CLN-619 alone and in combination with pembrolizumab in solid tumors, with anticipated updated clinical data in Q2 2024 CAMBRIDGE, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the U.S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.0001 per share CGEM The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FRO ...

There is a compelling biological and clinical rationale for targeting • 10 mg/kg: 1 ovarian (ongoing after 3 cycles), 1 cervical (ongoing after 6 cycles) 0 10 20 30 0 Stu y Duration ( eeks) MICA-NKG2D Binding in Presence of CLN-619 Abs References 1. Chihara et al. Lancet 2022. 2. Papadopoulos et al. ASCO 2019. 3. Bendell et al. AACR 2020. 4. Patients who underwent at least one RECIST response assessment or who had clinically assessed PD prior to first planned assessment 5. Endometrial, cervical, and ovarian ...

26 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized. Cullinan Oncology, Inc. Date: August 10, 2023 By : /s/ Nadim Ahmed Name: Nadim Ahmed Title: President and Chief Executive Officer (Principal Executive Officer) Date: August 10, 2023 By : /s/ Jeffrey Trigilio Name: Jeffrey Trigilio Title: Chief Financial Officer (Principal Financial and Accounting Of ...

1. CTCAE v5.0. 2. 100 mg patient with Gr3 pneumonitis confounded by recent treatment with CPI and concurrent hydropneumothorax in contralateral lung; 150 mg patient with Gr3 pneumonitis confounded by concurrent pneumocystis infection, had stopped zipalertinib 3 weeks prior to event; 100 mg patient with grade 1 pneumonitis treated with steroids with resolution and continued therapy; 65 mg patient with Gr 2 pneumonitis previously had pneumonitis on osimertinib. 16 Zipalertinib Phase 1/2a and pivotal study des ...

See accompanying notes to the unaudited consolidated financial statements. Item 1. Financial Statements. CULLINAN ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS (unaudited) (in thousands, except share amounts) Current liabilities: Accounts payable $ 2,031 $ 2,660 Accrued expenses and other current liabilities 18,379 14,135 Income tax payable 4,207 4,282 Operating lease liabilities, current 1,554 1,421 Total current liabilities 26,171 22,498 Long-term liabilities: Operating lease liabilities, net of current port ...

Some of our of icers and directors currently serve, and in the future may serve, as directors or of icers of our subsidiaries, and, as a result, have and may continue to have, fiduciary and other duties to our subsidiaries causing conflicts of interest with respect to their duties to us and their duties to our subsidiaries and in determining how to devote themselves to our af airs and the af airs of our subsidiaries. Our subsidiaries' partners may also disagree with the suf iciency of resources that we prov ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39856 CULLINAN ONCOLOGY, INC. (Exact name of Registrant as specified in its Charter) Delaware 81-3879991 (State or other ju ...

| --- | --- | --- | --- | |---------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | Mining for Tomorrow's Cures Cullinan Oncology Overview | | | | | Q3 2022 | | | | 2 Important notice and disclaimers This Presentation contains forward-looking statements and information. All statements other than statements of historical facts contained in this Presentation, including statements regarding our strategy, future financial condition, future operations, projected co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.0001 per share CGEM The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO ...